7,132 Shares in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Purchased by MBB Public Markets I LLC

MBB Public Markets I LLC acquired a new position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 7,132 shares of the company’s stock, valued at approximately $982,000.

Several other institutional investors have also added to or reduced their stakes in the company. Vanguard Group Inc. raised its holdings in shares of Neurocrine Biosciences by 2.3% in the first quarter. Vanguard Group Inc. now owns 9,930,926 shares of the company’s stock worth $1,369,673,000 after buying an additional 220,598 shares during the period. Renaissance Technologies LLC increased its stake in Neurocrine Biosciences by 9.6% in the second quarter. Renaissance Technologies LLC now owns 2,468,146 shares of the company’s stock worth $339,790,000 after purchasing an additional 216,500 shares during the period. AQR Capital Management LLC lifted its position in shares of Neurocrine Biosciences by 23.0% during the second quarter. AQR Capital Management LLC now owns 1,223,055 shares of the company’s stock worth $166,959,000 after purchasing an additional 228,444 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Neurocrine Biosciences by 1.4% during the second quarter. Bank of New York Mellon Corp now owns 934,404 shares of the company’s stock valued at $128,639,000 after purchasing an additional 13,069 shares during the period. Finally, Vestal Point Capital LP bought a new position in shares of Neurocrine Biosciences in the fourth quarter worth about $105,408,000. Institutional investors own 92.59% of the company’s stock.

Insiders Place Their Bets

In related news, Director William H. Rastetter sold 14,250 shares of the firm’s stock in a transaction on Thursday, August 15th. The shares were sold at an average price of $146.69, for a total transaction of $2,090,332.50. Following the completion of the transaction, the director now owns 37,491 shares of the company’s stock, valued at $5,499,554.79. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other Neurocrine Biosciences news, Director William H. Rastetter sold 14,250 shares of the business’s stock in a transaction that occurred on Thursday, August 15th. The stock was sold at an average price of $146.69, for a total value of $2,090,332.50. Following the completion of the transaction, the director now directly owns 37,491 shares of the company’s stock, valued at $5,499,554.79. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Ingrid Delaet sold 7,143 shares of the company’s stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $150.10, for a total value of $1,072,164.30. Following the completion of the sale, the insider now owns 2,507 shares in the company, valued at approximately $376,300.70. The disclosure for this sale can be found here. In the last ninety days, insiders sold 61,798 shares of company stock valued at $9,274,196. 4.30% of the stock is owned by insiders.

Neurocrine Biosciences Price Performance

NASDAQ NBIX opened at $115.22 on Tuesday. The company has a market cap of $11.60 billion, a price-to-earnings ratio of 31.74 and a beta of 0.37. The stock’s fifty day moving average price is $135.50 and its 200 day moving average price is $137.42. Neurocrine Biosciences, Inc. has a 1 year low of $103.63 and a 1 year high of $157.98.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its quarterly earnings data on Thursday, August 1st. The company reported $0.63 earnings per share for the quarter, missing analysts’ consensus estimates of $1.15 by ($0.52). Neurocrine Biosciences had a net margin of 16.00% and a return on equity of 14.86%. The firm had revenue of $590.20 million during the quarter, compared to analyst estimates of $545.98 million. During the same period in the prior year, the company posted $0.95 earnings per share. The firm’s revenue for the quarter was up 30.4% on a year-over-year basis. Research analysts expect that Neurocrine Biosciences, Inc. will post 4.19 earnings per share for the current year.

Analysts Set New Price Targets

NBIX has been the subject of several research reports. Oppenheimer boosted their price objective on shares of Neurocrine Biosciences from $216.00 to $219.00 and gave the company an “outperform” rating in a research report on Friday, August 2nd. Royal Bank of Canada dropped their price objective on Neurocrine Biosciences from $143.00 to $136.00 and set a “sector perform” rating on the stock in a research note on Thursday, August 29th. Jefferies Financial Group lifted their target price on Neurocrine Biosciences from $177.00 to $189.00 and gave the company a “buy” rating in a research report on Monday, August 19th. Barclays dropped their price target on Neurocrine Biosciences from $180.00 to $160.00 and set an “overweight” rating on the stock in a research report on Monday, September 9th. Finally, BMO Capital Markets lowered their price objective on shares of Neurocrine Biosciences from $142.00 to $128.00 and set a “market perform” rating for the company in a research note on Thursday, August 29th. Five investment analysts have rated the stock with a hold rating, eighteen have given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, Neurocrine Biosciences currently has an average rating of “Moderate Buy” and a consensus target price of $162.20.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.